Semaglutide started as a diabetes drug. It became a weight loss drug. Now the longevity research community is paying very close attention to something the clinical trials keep showing: the benefits go way beyond weight. This is an honest look at what the data actually shows — what's real, what's speculative, and what you need to know.
What GLP-1 Drugs Actually Do
GLP-1 (glucagon-like peptide-1) agonists mimic a hormone your gut naturally produces after eating. They slow gastric emptying (you feel full longer), suppress appetite at the hypothalamus level, stimulate insulin release in response to glucose, and inhibit glucagon release (reduces liver glucose production). The weight loss effect is the byproduct of these mechanisms. But those mechanisms have downstream effects that are getting researchers very interested.
The Cardiovascular Data Is Striking
The SELECT trial (2023) is the landmark study. It randomized 17,604 adults with obesity and existing cardiovascular disease to semaglutide 2.4mg or placebo. The results: a 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death). This was a cardiovascular outcome trial — not a weight loss trial. The cardiovascular benefit appeared to exceed what would be expected from weight loss alone.
MACE (major adverse cardiovascular events) is one of the primary outcome measures in longevity medicine. A 20% reduction is not a small effect.
The Emerging Inflammation Connection
GLP-1 agonists appear to have direct anti-inflammatory effects independent of weight loss. Studies show reduced CRP and IL-6 levels, reduced inflammatory markers in cardiac tissue, and possible direct effects on microglia (brain immune cells). The mechanism isn't fully understood, but the inflammation reduction is consistent across multiple trial populations.
Neurological Research: Early But Interesting
The drug tirzepatide (Mounjaro/Zepbound) is now being studied for Alzheimer's disease. GLP-1 receptors are present in the brain. The hypothesis: GLP-1 agonists may reduce neuroinflammation and improve insulin signaling in the brain, both implicated in Alzheimer's pathology. The EVOKE trial (liraglutide in early Alzheimer's) showed slowed progression on imaging. It's one trial, but the signal is there.
The Counterpoints (This Is Important)
- Muscle mass loss: GLP-1 agonists cause weight loss of both fat and muscle. Studies show approximately 25-40% of total weight lost is lean mass — a significant problem from a longevity perspective. Anyone using these drugs should be doing resistance training and consuming adequate protein (1.6-2.2g/kg bodyweight).
- Long-term data gaps: SELECT was 3 years. Longevity research cares about decades.
- Rebound risk: Most people regain weight when they stop. The drug doesn't address the underlying behaviors.
- Side effects: Nausea, vomiting, gastroparesis in some users. Rare but serious: pancreatitis risk. Contraindicated in personal/family history of medullary thyroid cancer.
- Cost: $900-1,200/month without insurance.
Who Might Actually Benefit
Based on current evidence, the clearest case for GLP-1 agonists in a longevity context:
- Adults with BMI >30 + existing cardiovascular disease or high cardiovascular risk
- Adults with type 2 diabetes or prediabetes + metabolic syndrome
- People who have tried diet/exercise interventions and have significant visceral adiposity that isn't responding
This is not a drug for people who are metabolically healthy and want to lose 15 pounds.
What to Measure Before Considering GLP-1s
Marek Health runs comprehensive metabolic panels including fasting insulin, HbA1c, ApoB, and CRP — the markers that tell you whether your risk profile justifies this class of drug. Talk to a physician who understands the longevity context.
The Takeaway
GLP-1 agonists are the most interesting new pharmacological tool in cardiometabolic medicine in 20 years. The cardiovascular outcome data is real. The inflammation signal is intriguing. They are not a longevity drug for healthy people — they are a powerful intervention for people with significant metabolic risk, with real tradeoffs that need to be managed. Watch this space. The Alzheimer's trials will be definitive.